Pneumology - Original Articles
18 September 2025

Clinico-etiological profile and treatment outcome of hospitalized diffuse parenchymal lung disease patients: a prospective cohort study

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
87
Views
61
Downloads

Authors

Diffuse parenchymal lung disease (DPLD) is a group of more than 200 pulmonary diseases that affect the alveoli, pulmonary interstitium, and/or small airways. DPLD patients often present in the outpatient department and inpatient department with acute/subacute worsening in their symptoms. These worsenings are due to a variety of causes that include acute exacerbations (AE), bacterial/viral/fungal infections, pneumothorax, pulmonary thromboembolism, or cardiac compromise. However, regardless of the type of underlying DPLD and the etiology of acute worsening when AE develops, it poses serious difficulties for patients, families, doctors, and the medical system. The current study was performed to evaluate the clinical presentation, etiological factors, and hospital course of DPLD patients presenting with acute/subacute worsening in their respiratory symptoms. A total of 39 hospitalized DPLD patients were recruited as per the inclusion and exclusion criteria. On admission, all relevant investigations were done, and the patients were evaluated thoroughly. All these patients were managed as per standard guidelines with regular monitoring. Based on the clinical course, treatment outcome was categorized as improved (discharged from hospital) or shifted to intensive care unit/mechanical ventilation and improved or died. The mean age of the study subjects was 57.95±11.7 years. The most common symptom reported in the study was dyspnea, followed by cough and fever. The most common etiology observed in the study, leading to hospital admission in DPLD patients, was respiratory infections and AE, followed by cardiac diseases. Out of the total 39 hospitalized DPLD patients, 13 patients required invasive mechanical ventilation, whereas 26 patients (66.7%) were managed with oxygen support/non-invasive ventilation/high-flow nasal oxygen. The univariate logistic analysis showed that patients with diabetes, pedal edema, idiopathic pulmonary fibrosis, regional wall motion abnormalities, and cardiac causes of acute clinical worsening were significant risk factors for the need for mechanical ventilation. On performing multivariate regression, none of the variables was an independent significant risk factor of mechanical ventilation. It is recommended to actively undertake monitoring and treating DPLD in conjunction with managing various concomitant illnesses, which is vital for improving outcomes and lowering the risk of acute clinical worsening and respiratory compromise.

Altmetrics

Downloads

Download data is not yet available.

Citations

Singh S, Sharma BB, Bairwa M, et al. Management of interstitial lung diseases: a consensus statement of the Indian Chest Society and National College of Chest Physicians. Lung India 2020;37:359-78. DOI: https://doi.org/10.4103/lungindia.lungindia_275_20
Saha K. Interstitial lung disease: diagnostic approach. J Assoc Chest Physicians 2014;2:3-15. DOI: https://doi.org/10.4103/2320-8775.126502
Travis WD, Hunninghake G, King Jr TE. Idiopathic nonspecific interstitial pneumonia: report of an American thoracic society project. Am J Respir Crit Care Med 2008;177:1338-47. DOI: https://doi.org/10.1164/rccm.200611-1685OC
Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43. DOI: https://doi.org/10.1164/rccm.200703-463PP
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824. DOI: https://doi.org/10.1164/rccm.2009-040GL
Sim JK, Oh JY, Lee EJ, et al. Serum procalcitonin for differential diagnosis of acute exacerbation and bacterial pneumonia in patients with interstitial lung disease. Am J Med Sci 2016;351:499-505. DOI: https://doi.org/10.1016/j.amjms.2016.02.029
Nishimoto K, Fujisawa T, Yoshimura K, et al. The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis. Respirology 2018;23:519-25. DOI: https://doi.org/10.1111/resp.13219
Keane MP, Arenberg DA, Lynch JP 3rd, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997;159:1437-43. DOI: https://doi.org/10.4049/jimmunol.159.3.1437
Agrawal A, Verma I, Shah V, et al. Cardiac manifestations of idiopathic pulmonary fibrosis. Intractable Rare Dis Res 2016;5:70-5. DOI: https://doi.org/10.5582/irdr.2016.01023
Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med 2018;378:1811-23. DOI: https://doi.org/10.1056/NEJMra1705751
Alhamad EH, CalJG, Alrajhi NN, AlBoukai AA. Acute exacerbation in interstitial lung disease. Ann Thorac Med 2021;16:178-87. DOI: https://doi.org/10.4103/atm.atm_14_21
Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. Significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959;2:257-66. DOI: https://doi.org/10.1136/bmj.2.5147.257
Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 2016;194:265-75. DOI: https://doi.org/10.1164/rccm.201604-0801CI
Leuschner G, Behr J. Acute exacerbation in interstitial lung disease. Front Med 2017;4:176. DOI: https://doi.org/10.3389/fmed.2017.00176
Shafeeq KM, Anithakumari K, FathahudeenA, et al. Aetiology and clinic radiological profile of interstitial lung disease in a tertiary care centre. Pulmonology 2011;13:12-5.
Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006;27:143-50. DOI: https://doi.org/10.1183/09031936.06.00114004
Magdy M, Saaed Z, Abd El-Aleem E, Mahmoud M. Clinical and radiological signs of acute exacerbation of interstitial lung diseases. Minia J Med Res 2019;30:116-9. DOI: https://doi.org/10.21608/mjmr.2022.221906
Salonen J, Purokivi M, Bloigu R, Kaarteenaho R. Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases. BMJ Open Respir Res 2020;7:563. DOI: https://doi.org/10.1136/bmjresp-2020-000563
Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: Incidence, risk factors and outcome. Eur Respir J 2011;37:356-63. DOI: https://doi.org/10.1183/09031936.00159709
Salonen J, Vähänikkilä H, Purokivi M, Kaarteenaho R. Causes of acute respiratory hospitalizations predict survival in fibrosing interstitial lung diseases. PLoS One 2020;15:e0242860. DOI: https://doi.org/10.1371/journal.pone.0242860
Miyazaki Y, Tateishi T, Akashi T, et al. Clinical predictors and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis. Chest 2008;134:1265-70. DOI: https://doi.org/10.1378/chest.08-0866
Rajasurya V, Gunasekaran K, Surani S. Interstitial lung disease and diabetes. World J Diabetes 2020;11:351-7. DOI: https://doi.org/10.4239/wjd.v11.i8.351
Wong AW, Lee TY, Johannson KA, et al. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respir Res 2020;21:322. DOI: https://doi.org/10.1186/s12931-020-01579-7
Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med 2014;108:647-53. DOI: https://doi.org/10.1016/j.rmed.2014.01.008
Judge EP, Fabre A, Adamali HI, Egan JJ. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 2012;40:93-100. DOI: https://doi.org/10.1183/09031936.00115511
Kärkkäinen M, Nurmi H, Kettunen HP, et al. Underlying and immediate causes of death in patients with idiopathic pulmonary fibrosis. BMC Pulm Med 2018;18:69. DOI: https://doi.org/10.1186/s12890-018-0642-4
Suzuki A, Kondoh Y, Brown KK, et al. Acute exacerbations of fibrotic interstitial lung diseases. Respirology 2020;25:525-34. DOI: https://doi.org/10.1111/resp.13682
Ryerson CJ, Collard HR. Acute exacerbations complicating interstitial lung disease. Curr Opin Pulm Med 2014;20:436-41. DOI: https://doi.org/10.1097/MCP.0000000000000073

Ethics approval

The study protocol was approved by the Ethical Review Committee of GMCH -32 Chandigarh. (No./GMCH/IEC/775R/2022/166).

How to Cite



“Clinico-Etiological Profile and Treatment Outcome of Hospitalized Diffuse Parenchymal Lung Disease Patients: A Prospective Cohort Study”. 2025. Monaldi Archives for Chest Disease, September. https://doi.org/10.4081/monaldi.2025.3508.